Sugi Predict

Sugi Predict / Compounds / SCHEMBL2195584

SCHEMBL2195584

SCHEMBL2195584

Cn1nc(-c2ccccc2)[nH]c1=[Pt].FC(F)(F)c1ccc(CN(I)I)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 1/20 0.38
▸ SCN2A Q99250 2/20 0.38
▸ MAPK13 O15264 2/20 0.37
▸ RAF1 P04049 2/20 0.37
▸ MAPK12 P53778 2/20 0.37
▸ MAPK11 Q15759 2/20 0.37
▸ MAPK14 Q16539 2/20 0.37
▸ PDE2A O00408 1/20 0.36
▸ NPBWR1 P48145 1/20 0.35
▸ EPHX2 P34913 1/20 0.34
▸ KIF11 P52732 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ TNKS O95271 1/20 0.34
▸ WNT3A P56704 1/20 0.34
▸ TNKS2 Q9H2K2 1/20 0.34
▸ DGAT1 O75907 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ MAPK9 P45984 1/20 0.33
▸ CYP19A1 P11511 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2197165 0.88 CSF1R (0.38) CXCR2KDM4EALDH1A1
SCHEMBL2193102 0.87 ALOX5 (0.40) MAPK13MAPK12MAPK11MAPK14CYP19A1
SCHEMBL2193790 0.86 CYP19A1 (0.38) POLBCYP19A1NPSR1MEN1KMT2A
SCHEMBL2194610 0.85 CYP19A1 (0.37) CXCR2SCN2AMAPK13RAF1MAPK12
SCHEMBL2193608 0.85 MAPK13 (0.36) MAPK13MAPK12MAPK11MAPK14DGAT1
SCHEMBL2195103 0.83 PDE2A (0.35) CXCR2PDE2APOLBMEN1KMT2A
SCHEMBL2194836 0.83 PDE2A (0.35) CXCR2PDE2APOLBMEN1KMT2A
SCHEMBL2192771 0.81 LMNA (0.33) MEN1KMT2AKDM4E
SCHEMBL2196384 0.81 PDE5A (0.36) PDE2A
SCHEMBL2197113 0.78 PDE5A (0.35) PDE2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 — — US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 — — US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 — — US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 — — US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 CXCR2 69/4885SCN2A 2078/4885MAPK13 3538/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 CXCR2 69/4885SCN2A 2078/4885MAPK13 3538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.